KR101256400B1 - 항체 - Google Patents

항체 Download PDF

Info

Publication number
KR101256400B1
KR101256400B1 KR1020067024896A KR20067024896A KR101256400B1 KR 101256400 B1 KR101256400 B1 KR 101256400B1 KR 1020067024896 A KR1020067024896 A KR 1020067024896A KR 20067024896 A KR20067024896 A KR 20067024896A KR 101256400 B1 KR101256400 B1 KR 101256400B1
Authority
KR
South Korea
Prior art keywords
antibody
ser
seq
gly
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067024896A
Other languages
English (en)
Korean (ko)
Other versions
KR20070020048A (ko
Inventor
롱-화 린
충 난 창
페이-지운 첸
치-첸 황
Original Assignee
압제노믹스 코오페라티에프 유.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101256400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 압제노믹스 코오페라티에프 유.에이. filed Critical 압제노믹스 코오페라티에프 유.에이.
Publication of KR20070020048A publication Critical patent/KR20070020048A/ko
Application granted granted Critical
Publication of KR101256400B1 publication Critical patent/KR101256400B1/ko
Assigned to 알트루바이오 인코퍼레이티드 reassignment 알트루바이오 인코퍼레이티드 권리의 전부이전등록 Assignors: 압제노믹스 코오페라티에프 유.에이.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020067024896A 2004-05-10 2005-05-10 항체 Expired - Fee Related KR101256400B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
US60/569,892 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies

Publications (2)

Publication Number Publication Date
KR20070020048A KR20070020048A (ko) 2007-02-16
KR101256400B1 true KR101256400B1 (ko) 2013-04-26

Family

ID=35394680

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067024896A Expired - Fee Related KR101256400B1 (ko) 2004-05-10 2005-05-10 항체

Country Status (27)

Country Link
US (8) US7604800B2 (cg-RX-API-DMAC7.html)
EP (3) EP2377890B1 (cg-RX-API-DMAC7.html)
JP (4) JP5623690B2 (cg-RX-API-DMAC7.html)
KR (1) KR101256400B1 (cg-RX-API-DMAC7.html)
CN (2) CN1984680B (cg-RX-API-DMAC7.html)
AR (1) AR048781A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005244072C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510567B8 (cg-RX-API-DMAC7.html)
CA (3) CA2907141C (cg-RX-API-DMAC7.html)
DK (1) DK1765396T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP067056A (cg-RX-API-DMAC7.html)
EG (1) EG26781A (cg-RX-API-DMAC7.html)
ES (3) ES2448468T3 (cg-RX-API-DMAC7.html)
IL (3) IL178838A (cg-RX-API-DMAC7.html)
MX (1) MXPA06012986A (cg-RX-API-DMAC7.html)
MY (1) MY148646A (cg-RX-API-DMAC7.html)
NO (1) NO341844B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ590690A (cg-RX-API-DMAC7.html)
PH (1) PH12015500247A1 (cg-RX-API-DMAC7.html)
PL (1) PL1765396T3 (cg-RX-API-DMAC7.html)
PT (1) PT1765396E (cg-RX-API-DMAC7.html)
RU (1) RU2482131C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201606541UA (cg-RX-API-DMAC7.html)
TW (2) TWI402274B (cg-RX-API-DMAC7.html)
UA (1) UA100356C2 (cg-RX-API-DMAC7.html)
UY (1) UY28886A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005110475A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
TWI659474B (zh) * 2008-10-31 2019-05-11 Semiconductor Energy Laboratory Co., Ltd. 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
IN2015DN02826A (cg-RX-API-DMAC7.html) * 2009-09-03 2015-09-11 Merck Sharp & Dohme
WO2012000094A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) * 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
WO2013057096A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
US10988528B2 (en) * 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
WO2017120534A1 (en) * 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
KR20220042055A (ko) * 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
JP2024540484A (ja) * 2021-11-17 2024-10-31 アルトゥルバイオ, インコーポレイテッド 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049252A1 (en) 2001-08-03 2003-03-13 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
RU2151612C1 (ru) * 1992-12-01 2000-06-27 Протеин Дизайн Лэбс, Инк. Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE69415154T2 (de) * 1993-01-25 1999-07-29 Dana-Farber Cancer Institute, Inc., Boston, Mass. Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
CN1124928A (zh) * 1993-05-04 1996-06-19 赛特尔公司 P-选择蛋白抗体及其应用
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE69630307T2 (de) 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CN1342085A (zh) * 1998-10-30 2002-03-27 遗传研究所有限公司 通过p-选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
WO2002022820A1 (en) * 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
PL366223A1 (en) 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049252A1 (en) 2001-08-03 2003-03-13 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1

Also Published As

Publication number Publication date
NO341844B1 (no) 2018-02-05
UY28886A1 (es) 2005-12-30
CA2907141C (en) 2016-05-31
US7604800B2 (en) 2009-10-20
KR20070020048A (ko) 2007-02-16
US10030075B2 (en) 2018-07-24
JP2014223084A (ja) 2014-12-04
AU2005244072C1 (en) 2012-09-20
MXPA06012986A (es) 2007-02-12
PL1765396T3 (pl) 2014-07-31
EP2377890B1 (en) 2016-08-10
IL228032A0 (en) 2013-09-30
CA2907141A1 (en) 2005-11-24
BRPI0510567A (pt) 2007-11-20
TW201313740A (zh) 2013-04-01
EP1765396A2 (en) 2007-03-28
HK1102760A1 (en) 2007-12-07
TWI448474B (zh) 2014-08-11
AU2005244072A1 (en) 2005-11-24
NZ590690A (en) 2012-10-26
US8828397B2 (en) 2014-09-09
ES2598034T3 (es) 2017-01-24
US20130101587A1 (en) 2013-04-25
RU2006143686A (ru) 2008-06-20
US8287871B2 (en) 2012-10-16
US20110172397A1 (en) 2011-07-14
JP2007536933A (ja) 2007-12-20
NZ578647A (en) 2012-04-27
TWI402274B (zh) 2013-07-21
EP2377890A2 (en) 2011-10-19
JP2011200247A (ja) 2011-10-13
IL228033A0 (en) 2013-09-30
SG10201606541UA (en) 2016-09-29
CN103980361A (zh) 2014-08-13
AU2005244072B2 (en) 2012-05-31
ES2448468T3 (es) 2014-03-14
EG26781A (en) 2014-09-07
CA2812040C (en) 2016-05-03
BRPI0510567B1 (pt) 2018-11-13
US8361472B2 (en) 2013-01-29
US20090191204A1 (en) 2009-07-30
EP2377889A3 (en) 2012-03-28
CN1984680B (zh) 2014-11-05
EP2377889A2 (en) 2011-10-19
EP1765396B1 (en) 2013-11-20
RU2482131C2 (ru) 2013-05-20
WO2005110475A3 (en) 2006-02-23
EP2377890A3 (en) 2011-12-28
NO20065542L (no) 2007-01-31
US20170190782A1 (en) 2017-07-06
IL178838A (en) 2017-08-31
JP5623690B2 (ja) 2014-11-12
JP2014094010A (ja) 2014-05-22
CN103980361B (zh) 2017-06-23
AR048781A1 (es) 2006-05-24
PT1765396E (pt) 2014-02-25
TW200536860A (en) 2005-11-16
WO2005110475A2 (en) 2005-11-24
US20050266003A1 (en) 2005-12-01
CA2566305A1 (en) 2005-11-24
NZ551626A (en) 2010-03-26
IL178838A0 (en) 2007-03-08
US8663641B2 (en) 2014-03-04
US20090198044A1 (en) 2009-08-06
US20130102762A1 (en) 2013-04-25
US9631019B2 (en) 2017-04-25
EP1765396A4 (en) 2008-07-02
PH12015500247A1 (en) 2015-12-14
ECSP067056A (es) 2007-01-26
CA2812040A1 (en) 2005-11-24
CA2566305C (en) 2014-10-14
SG187443A1 (en) 2013-02-28
ES2602633T3 (es) 2017-02-21
US20150183870A1 (en) 2015-07-02
CN1984680A (zh) 2007-06-20
DK1765396T3 (en) 2014-02-24
BRPI0510567B8 (pt) 2021-05-25
MY148646A (en) 2013-05-15
EP2377889B1 (en) 2016-07-13
UA100356C2 (ru) 2012-12-25

Similar Documents

Publication Publication Date Title
US10030075B2 (en) Methods of treating with anti-PSGL-1 antibodies
AU2012201999B2 (en) Antibodies
HK1102760B (en) Anti-psgl-1 antibodies
HK1163138A (en) Antibodies
HK1163139A (en) Antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20160328

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180330

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190329

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250416

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250416

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250416